LSL Pharma Group

LSL Pharma Group EBITDA per Share

EBITDA per Share of LSL Pharma Group (LSL.V) as of Nov 1, 2026.

EBITDA per Share

0.00CAD

YoY

-95.67%

Last updated:

EBITDA per Share of LSL Pharma Group is 2025 0.00 CAD. EBITDA per Share of LSL Pharma Group was 2024 0.01 CAD. It decreases by -95.67% lower compared to the previous year.

The LSL Pharma Group EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2020
0.01 CAD
Jan 1, 2021
-0.00 CAD
Jan 1, 2022
-0.08 CAD
Jan 1, 2023
-0.08 CAD
Jan 1, 2024
0.01 CAD
Jan 1, 2025
0.00 CAD
The LSL Pharma Group EBITDA per Share history
YEAREBITDA per ShareYoY
0.00CAD-95.67%
0.01CAD-106.39%
-0.08CAD-1.69%
-0.08CAD+10,128.75%
-0.00CAD-108.06%
0.01CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

LSL Pharma Group Stock analysis

What does LSL Pharma Group do? LSL Pharma Group, Inc. generates revenue through the development, manufacturing, and distribution of natural health products and dietary supplements in solid dosage forms, as well as sterile ophthalmic pharmaceutical products. The company operates as a pharmaceutical entity specializing in these specific therapeutic and wellness categories to meet market demand. The firm utilizes its subsidiaries, including Steri-Med Pharma Inc., LSL Laboratory Inc., and Groupe Immobilier LSL inc., to support its core operations. These entities facilitate the company's ability to produce and distribute its specialized pharmaceutical and supplement offerings effectively within its operational framework. LSL Pharma Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LSL Pharma Group stock

On Eulerpool you can find the complete historical development of EBITDA per Share LSL Pharma Group since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — LSL Pharma Group

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — LSL Pharma Group